The WRAP53 gene is localized on chromosome 17p13.1 and contains 13 exons, including three alternative starting exons generating at least three gene products. The WRAP53 gene partially overlaps the p53tumor suppressor gene in a head-to-head orientation.
Function of WRAP53α and WRAP53γ
Transcripts of WRAP53 that overlap the first exon of p53 regulate the levels of p53 mRNA and protein. WRAP53γ transcripts overlap the first intron of p53 and are antisense to the previously identified transcript Hp53int1 localized within this intron. However, the function of WRAP53γ remains elusive.
Function of WRAP53β protein
The WRAP53 gene also encodes a protein termed WRAP53β, which belongs to the WD40 protein family. WRAP53β facilitates protein-protein and protein-RNA interactions and directs factors to nuclear organelles Cajal bodies, to telomeres and to DNA double-strand breaks. Factors localized to Cajal bodies with the help of WRAP53β includes the SMN protein, small Cajal body-specific RNAs and the enzyme telomerase. WRAP53β also targets the ubiquitin ligase RNF8 to DNA double-strand breaks. In addition to localizing factors to correct cellular sites, WRAP53β maintain structural integrity of Cajal bodies and without WRAP53β these organelles collapse and cannot re-form .
Domains of WRAP53β
The WRAP53β protein is highly evolutionary conserved, with homologs in vertebrates, invertebrates, plants and yeast. WRAP53β consists of a proline-rich N-terminus, a central WD40 domain and a glycine-rich C-terminus. The WD40 domain of WRAP53β serves as a scaffold for multiple interactions between a wide variety of molecules.
Germline mutations in WRAP53β result in disorder known as dyskeratosis congenita, characterized by bone marrow failure, premature ageing, predisposition for cancer and a triad of mucocutaneous features including oral leukoplakia, abnormal skin pigmentation and nail dystrophy. Mutations in WRAP53β are inherited in an autosomal recessive fashion, reside in highly conserved regions of its WD40 domain and result in a more severe form of this disease. These mutations reduce the nuclear level of WRAP53β, impair its trafficking of telomerase to telomeres, and subsequently lead to progressive shortening of telomeres in these patients The chaperonin CCT/TRiC is crucial for proper folding of WRAP53β and this folding is impaired in dyskeratosis congenita
Defective WRAP53β-mediated trafficking of SMN is observed in patients afflicted by the most severe form of spinal muscular atrophy, a neurodegenerative disorder characterized by progressive degeneration of spinal cord anterior horn α-motor neurons and the leading genetic cause of infant mortality with an incidence of approximately 1:6000 live births. Mutations in the SMN1 gene are the underlying cause to spinal muscular atrophy.
WRAP53β and cancer
WRAP53β is overexpressed in a variety of cancer cell lines of different origins and such overexpression promotes carcinogenic transformation indicating that this protein possesses oncogenic properties. WRAP53β is overexpressed in primary nasopharyngeal carcinoma, esophageal squamous cell carcinoma and rectal cancer. Moreover, knockdown of WRAP53β in cancer cells reduced the size of the tumors formed when these are grafted into mice and triggers mitochondrial-dependent apoptosis in cancer cells. In contrary, inactivating mutations in both alleles of WRAP53β causes dyskeratosis congenita, indicating that this protein acts as tumor suppressor, rather than an oncogene. Loss of nuclear WRAP53β is also correlated with shortened survival and resistance to radiotherapy in patients with head and neck cancer. With its complex roles in a number of cellular processes, WRAP53β may act as a tumor suppressor under certain conditions and as an oncogene in under others. Single nucleotide polymorphisms in the WRAP53 gene have been linked to an increased risk for breast and ovarian cancer. One of these SNPs also associate with defective DNA repair and hematotoxicity in workers exposed to benzene
Discovery
The WRAP53 gene was first identified by Marianne Farnebo at Karolinska Institutet in 2006. In 2009 the WRAP53β protein was described by Steven Artandi, Joan Steitz and Marianne Farnebo independently.
